Mounjaro weekly weight loss: what the evidence actually shows

You've just started Mounjaro and the first few weeks feel slow

That experience is common, and it makes clinical sense. Treatment begins at 2.5mg, a dose chosen because your digestive system needs time to adjust, not because 2.5mg is where the therapeutic effect sits. Many people notice some nausea or reduced appetite in these early weeks, but the scale may not budge much. That can feel disheartening, particularly if you started with high expectations.

What is happening underneath is a gradual recalibration of appetite signals. The pen is teaching your system a new normal. On a week-by-week basis during this phase, losses of around 0.2–0.5 kg are not unusual, sometimes less, sometimes nothing at all. The more meaningful pattern tends to emerge between weeks four and eight, which is why tracking what happens across the first eight weeks gives a far more useful picture than scrutinising last Tuesday's reading.

One practical point: weighing yourself on the same day each week, at the same time of day, irons out the water-retention fluctuations that make daily readings misleading. First thing on a weekday morning tends to work well, before breakfast, before the school run, before anything else changes the number.

How Mounjaro produces weekly weight loss, the mechanism in plain terms

Tirzepatide activates both GIP and GLP-1 receptors simultaneously. GLP-1 agonism slows the rate at which food leaves the stomach, reduces appetite signals in the brain and improves insulin sensitivity. GIP agonism adds a separate layer, influencing fat metabolism and energy balance. The result is that most people eat substantially less, not through willpower, but because the physiological drive to eat is quieter. A closer look at how tirzepatide works sets out the biology in more detail.

The practical consequence for weekly weight loss is that the reduction tends to accelerate as the dose increases. At 2.5mg the effect is mild. At 10mg or 15mg, people often describe finding it genuinely easy to stop eating earlier, skip snacks without effort, and feel satisfied on smaller portions. The weekly losses this produces are real but rarely linear, a week with a stressful commute, a birthday dinner, or a stomach bug can shift the number in either direction without meaning the treatment has stopped working.

The week-by-week breakdown of typical Mounjaro progress gives a sense of how each phase tends to look across the treatment timeline.

What the trial data says about average weekly weight loss on Mounjaro

The SURMOUNT-1 trial, published in the New England Journal of Medicine, enrolled 2,539 adults with obesity but without diabetes over 72 weeks. At 15mg, participants lost around 20–21% of body weight on average. Dividing that across 72 weeks gives a rough average of just under 0.3% of body weight per week, but the actual distribution is front-loaded in the middle of treatment and flatter at the start and end.

Crucially, the trial figure is an average. Some participants lost more; others lost less. NICE reviewed this evidence when recommending tirzepatide (TA1026) for adults with a BMI of 35 or above alongside a weight-related condition, and the trial data formed the basis of that decision. For context on what that recommendation means for NHS and private access, the full Mounjaro weight-loss guide covers eligibility in detail. The NICE technology appraisal for tirzepatide and the original SURMOUNT-1 paper in the NEJM are both publicly available if you want to read the primary evidence.

One thing worth noting: if you are five weeks in and seeing little change, that is a recognised pattern rather than a failure. A dedicated page on stalled progress at week five addresses what typically lies behind it.

When weekly weight loss on Mounjaro slows or stalls

Plateaus happen. They are a normal part of how the body responds to sustained weight loss, not a sign that the medicine has stopped working. As weight falls, the body's energy requirements drop too, which can narrow the deficit that was producing weekly losses. This often coincides with a dose increase, during which the body is again adjusting and appetite suppression may temporarily dip.

Diet quality, protein intake, sleep and activity all influence how quickly weekly losses resume after a plateau. GLP-1 medicines reduce appetite but do not override the basic maths of energy balance entirely. A detailed look at per-week weight loss patterns explores the typical plateau points and what tends to shift them.

For people considering the financial side, understanding what the treatment involves over time is part of the picture, the Mounjaro cost guide sets out what private treatment typically involves. And if you are ready to discuss whether Mounjaro is clinically suitable for you, check your eligibility through a free consultation with one of our GPhC-registered prescribers.